Sanofi’s Alison Schecter Tapped as Selecta Bio Chief Medical Officer

Selecta Biosciences (NASDAQ: [[ticker:SELB]]) has appointed Alison Schecter to serve as chief medical officer. Schecter joins Watertown, MA-based Selecta from Sanofi (NYSE: [[ticker:SNY]]) where she was global project head in rare diseases. Her experience also includes positions at Baxalta, the Northeast J&J Innovation Center, and the Novartis Institutes of Biomedical Research. Lead Selecta drug candidate SEL-212, an experimental biological drug for gout, is currently in mid-stage clinical testing.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.